載入中
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
前收盤價
US$1.33
−US$0.11 · -7.64%
盤中時間採用ET。市場資料可能有所延遲。
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
日內區間
目前US$1.33
52週區間
目前US$1.33
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
43
合理估值
情緒
56
多空交錯
風險
66
高風險
動能
17
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
日內區間
目前US$1.33
52週區間
目前US$1.33
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 373.1萬 USD | 762萬 USD | 1703.4萬 USD | 1632萬 USD | 1182.7萬 USD |
| 銷售、一般及管理費用 | 298.3萬 USD | 293.5萬 USD | 484.4萬 USD | 596.2萬 USD | 582.1萬 USD |
| 營業費用 | 2745.8萬 USD | 1100.5萬 USD | 2227.1萬 USD | 2260.3萬 USD | 1793.4萬 USD |
| 利息收入 | 22.7萬 USD | 26萬 USD | 47.4萬 USD | 53.2萬 USD | 32萬 USD |
| 利息支出 | 3.9萬 USD | 4.1萬 USD | 5.6萬 USD | 6.7萬 USD | 7.9萬 USD |
| 折舊和攤銷 | 20.3萬 USD | 18.6萬 USD | 19.7萬 USD | 20.1萬 USD | 23.1萬 USD |
| 營業利益 | −2745.8萬 USD | −1100.5萬 USD | −2227.1萬 USD | −2260.3萬 USD | −1793.4萬 USD |
| 淨利 | −2638.6萬 USD | −724萬 USD | −1988萬 USD | −2166.8萬 USD | −1838.4萬 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年3月2日 | 1:10 | — | — |
股票分割 | 2024年9月17日 | 1:20 | — | — |
股票分割 | 2020年8月21日 | 1:10 | — | — |
已生效 2026年3月2日
1:10
已生效 2024年9月17日
1:20
已生效 2020年8月21日
1:10
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
